Mount Sinai Adopts SOPHiA DDM™ to Boost Cancer Genomics
Event summary
- Mount Sinai Health System will adopt SOPHiA GENETICS' AI-powered SOPHiA DDM™ Platform to enhance cancer research and genomic testing capabilities.
- The platform will strengthen next-generation sequencing (NGS) for blood cancers and solid tumors, reducing manual interpretation time.
- Mount Sinai supports care for over 4,000 oncology patients annually and is a National Cancer Institute-designated Comprehensive Cancer Center.
- The collaboration was announced at the AACR Annual Meeting in San Diego, April 16, 2026.
- Over 990 global institutions use SOPHiA GENETICS' decentralized platform to accelerate precision medicine.
The big picture
This collaboration underscores the growing trend of AI-driven precision medicine in oncology, with Mount Sinai's adoption of SOPHiA DDM™ highlighting the shift towards data-driven, scalable solutions in cancer care. The partnership aligns with broader industry movements towards integrating advanced analytics into clinical workflows to improve patient outcomes and operational efficiency. SOPHiA GENETICS' expanding network of over 990 institutions positions it as a key player in democratizing access to advanced genomic testing.
What we're watching
- Platform Scalability
- How SOPHiA DDM™ will handle the scale of Mount Sinai's genomic data and whether it can maintain efficiency.
- Market Expansion
- The pace at which SOPHiA GENETICS can onboard additional top-tier institutions to its network.
- Regulatory Compliance
- Whether Mount Sinai's independent validation and operation of SOPHiA DDM™ as a laboratory developed test (LDT) will face any regulatory hurdles.
Related topics